Chief Executive Officer
Receptor BioLogix

Tom Glaze has spent over 25 years in the biotechnology industry founding and managing companies in pharmaceuticals and medical devices. Prior to joining Receptor BioLogix, he founded Essentialis, Inc., a developer of obesity drugs, and Limerick NeuroSciences, Inc., established to develop new analgesics with reduced side effects. Additionally, he was the interim president and CEO of Palingen, Inc., a Bay Area biopharmaceutical company developing an antibody therapeutic to treat leukemia and lymphoma. Previously, he was founder and CEO for 11 years of Metabolex, Inc., a Bay Area biopharmaceutical company focused on therapeutics to treat diabetes.

In 1979, Mr. Glaze founded Monoclonal Antibodies, Inc., one of the first biotechnology companies to harness the power of antibodies to diagnose disease, and served as its chairman and CEO until its merger with Quidel Corp in 1991. In addition to being a board member of Receptor BioLogix, he also serves on the boards of Essentialis, Limerick NeuroSciences, Palingen, Leptogen, and BayBio. He serves as a consultant to several early-stage biotechnology companies, and is on the advisory boards of the Petit Institute for Bioengineering and Bioscience at Georgia Tech, and the Friday Harbor Labs of the University of Washington. Mr. Glaze holds an MBA and MS from Stanford University and a BIE from the Georgia Institute of Technology.